About 10 results found for searched term "328-50-7" (0.196 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M10100 | Opicapone | Transferase |
| BIA 9-1067 | ||
| Opicapone, also known as BIA 9-1067, is a novel potent and selective catechol-O-methyltransferase inhibitor (COMT inhibitor). | ||
| M11498 | 2-Ketoglutaric acid | Tyrosinase |
| alpha-ketoglutarate； alpha-ketoglutaric acid；2-oxoglutaric acid | ||
| 2-ketoglutaric acid (alpha-ketoglutaric acid) is an intermediate produced by ATP or GTP in the Krebs cycle. 2-ketoglutaric acid also acts as the main carbon skeleton for nitrogen assimilation. 2-ketoglutaric acid is a reversible inhibitor of Tyrosinase (IC50=15 mM). | ||
| M2831 | ME0328 | PARP |
| ME0328 is a potent and selective PARP inhibitor with IC50 of 0.89 μM for PARP3, about 7-fold selectivity over PARP1. | ||
| M2890 | NSC 632839 | Others |
| F6 | ||
| NSC 632839 is not only a DUB inhibitor, but also a deSUMOylase inhibitor, it inhibits USP2, USP7, and SENP2 with IC50 of 45 μM, 37 μM, and 9.8 μM, respectively. | ||
| M5318 | Zoligratinib | EGFR/HER2 |
| CH5183284;Debio 1347 | ||
| CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1. | ||
| M6263 | INCB3284 dimesylate | CCR |
| INCB 3284 dimesylate is a potent, selective and orally bioavailable hCCR2 antagonist with IC50 of 3.7 nM. | ||
| M8257 | SB 328437 | CCR |
| SB328437; SB-328437 | ||
| SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM. SB 328437 inhibits the recruitment and migration of eosinophils in allergen models of models. SB 328437 suppresses the Th2-mediated eosinophil infiltration in the airways. | ||
| M9884 | INCB3284 | CCR |
| INCB3284 free base | ||
| INCB3284 is a potent, selective, and orally bioavailable hCCR2 antagonist, exhibited an IC50 of 3.7 nM in antagonism of monocyte chemoattractant protein-1 binding to hCCR2. | ||
| M14307 | LY 3000328 | Cathepsin |
| LY 3000328 is a potent and selective Cathepsin S (Cat S) inhibitor with IC50s of 7.7 and 1.67 nM for hCat S and mCat S, respectively. | ||
| M24888 | Cetrelimab | PD-1/PD-L1 |
| JNJ 63723283; JNJ 3283 | ||
| Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
